These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29452352)

  • 21. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.
    Novak A; Barad L; Zeevi-Levin N; Shick R; Shtrichman R; Lorber A; Itskovitz-Eldor J; Binah O
    J Cell Mol Med; 2012 Mar; 16(3):468-82. PubMed ID: 22050625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin.
    Viatchenko-Karpinski S; Terentyev D; Györke I; Terentyeva R; Volpe P; Priori SG; Napolitano C; Nori A; Williams SC; Györke S
    Circ Res; 2004 Mar; 94(4):471-7. PubMed ID: 14715535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism.
    Faber GM; Rudy Y
    Cardiovasc Res; 2007 Jul; 75(1):79-88. PubMed ID: 17531962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.
    Kurtzwald-Josefson E; Hochhauser E; Bogachenko K; Harun-Khun S; Katz G; Aravot D; Seidman JG; Seidman CE; Eldar M; Shainberg A; Arad M
    Heart Rhythm; 2014 Aug; 11(8):1471-9. PubMed ID: 24768611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of cytosolic and intra-sarcoplasmic reticulum calcium waves by calsequestrin in rat cardiac myocytes.
    Kubalova Z; Györke I; Terentyeva R; Viatchenko-Karpinski S; Terentyev D; Williams SC; Györke S
    J Physiol; 2004 Dec; 561(Pt 2):515-24. PubMed ID: 15486014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing cationic selectivity of cardiac calsequestrin and its CPVT mutants.
    Bal NC; Jena N; Sopariwala D; Balaraju T; Shaikh S; Bal C; Sharon A; Gyorke S; Periasamy M
    Biochem J; 2011 Apr; 435(2):391-9. PubMed ID: 21265816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.
    Faggioni M; Hwang HS; van der Werf C; Nederend I; Kannankeril PJ; Wilde AA; Knollmann BC
    Circ Res; 2013 Feb; 112(4):689-97. PubMed ID: 23295832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.
    di Barletta MR; Viatchenko-Karpinski S; Nori A; Memmi M; Terentyev D; Turcato F; Valle G; Rizzi N; Napolitano C; Gyorke S; Volpe P; Priori SG
    Circulation; 2006 Sep; 114(10):1012-9. PubMed ID: 16908766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.
    Kurtzwald-Josefson E; Yadin D; Harun-Khun S; Waldman M; Aravot D; Shainberg A; Eldar M; Hochhauser E; Arad M
    Heart Rhythm; 2017 Jul; 14(7):1053-1060. PubMed ID: 28336343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
    Katz G; Arad M; Eldar M
    Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated junctional rhythm and nonalternans repolarization lability precede ventricular tachycardia in Casq2-/- mice.
    Mezu UL; Singh P; Shusterman V; Hwang HS; Knollmann BC; Němec J
    J Cardiovasc Electrophysiol; 2012 Dec; 23(12):1355-63. PubMed ID: 22860618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
    Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
    Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
    Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
    Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-natal heart adaptation in a knock-in mouse model of calsequestrin 2-linked recessive catecholaminergic polymorphic ventricular tachycardia.
    Valle G; Boncompagni S; Sacchetto R; Protasi F; Volpe P
    Exp Cell Res; 2014 Feb; 321(2):178-89. PubMed ID: 24370574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pacing Dynamics Determines the Arrhythmogenic Mechanism of the CPVT2-Causing CASQ2
    Paudel R; Jafri MS; Ullah A
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interplay between Triadin and Calsequestrin in the Pathogenesis of CPVT in the Mouse.
    Cacheux M; Fauconnier J; Thireau J; Osseni A; Brocard J; Roux-Buisson N; Brocard J; Fauré J; Lacampagne A; Marty I
    Mol Ther; 2020 Jan; 28(1):171-179. PubMed ID: 31607542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model.
    Rizzi N; Liu N; Napolitano C; Nori A; Turcato F; Colombi B; Bicciato S; Arcelli D; Spedito A; Scelsi M; Villani L; Esposito G; Boncompagni S; Protasi F; Volpe P; Priori SG
    Circ Res; 2008 Aug; 103(3):298-306. PubMed ID: 18583715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia.
    Josephs K; Patel K; Janson CM; Montagna C; McDonald TV
    Mol Genet Genomic Med; 2017 Nov; 5(6):788-794. PubMed ID: 29178653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling.
    Kirchhefer U; Wehrmeister D; Postma AV; Pohlentz G; Mormann M; Kucerova D; Müller FU; Schmitz W; Schulze-Bahr E; Wilde AA; Neumann J
    J Mol Cell Cardiol; 2010 Jul; 49(1):95-105. PubMed ID: 20302875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.